Amiodarone: Pharmacology and Antiarrhythmic and Adverse Effects

Gerald Naccarelli, Robert L. Rinkenberger, Anne H. Dougherty, Ruth A. Giebel

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Amiodarone is a benzofuran derivative that has been effective for the treatment of both supraventricular and ventricular tachyarrhythmias. It has a large volume of distribution, moderate bioavailability and a long half‐life. Its pharmacokinetics are not well understood and its tissue distribution is not typical of a 2‐compartment model. Due to ocular, dermatologic, gastrointestinal, neurologic, cardiovascular, thyroid and pulmonary toxicity, amiodarone should be reserved for use in patients with refractory and/or life‐threatening arrhythmias. 1985 Pharmacotherapy Publications Inc.

Original languageEnglish (US)
Pages (from-to)298-311
Number of pages14
JournalPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Volume5
Issue number6
DOIs
StatePublished - Jan 1 1985

Fingerprint

Amiodarone
Pharmacology
Tissue Distribution
Tachycardia
Nervous System
Biological Availability
Half-Life
Publications
Cardiac Arrhythmias
Thyroid Gland
Pharmacokinetics
Drug Therapy
Lung
Therapeutics
benzofuran

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Naccarelli, Gerald ; Rinkenberger, Robert L. ; Dougherty, Anne H. ; Giebel, Ruth A. / Amiodarone : Pharmacology and Antiarrhythmic and Adverse Effects. In: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 1985 ; Vol. 5, No. 6. pp. 298-311.
@article{3fcd6b4b0564492992042f6a2acde17d,
title = "Amiodarone: Pharmacology and Antiarrhythmic and Adverse Effects",
abstract = "Amiodarone is a benzofuran derivative that has been effective for the treatment of both supraventricular and ventricular tachyarrhythmias. It has a large volume of distribution, moderate bioavailability and a long half‐life. Its pharmacokinetics are not well understood and its tissue distribution is not typical of a 2‐compartment model. Due to ocular, dermatologic, gastrointestinal, neurologic, cardiovascular, thyroid and pulmonary toxicity, amiodarone should be reserved for use in patients with refractory and/or life‐threatening arrhythmias. 1985 Pharmacotherapy Publications Inc.",
author = "Gerald Naccarelli and Rinkenberger, {Robert L.} and Dougherty, {Anne H.} and Giebel, {Ruth A.}",
year = "1985",
month = "1",
day = "1",
doi = "10.1002/j.1875-9114.1985.tb03434.x",
language = "English (US)",
volume = "5",
pages = "298--311",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "6",

}

Amiodarone : Pharmacology and Antiarrhythmic and Adverse Effects. / Naccarelli, Gerald; Rinkenberger, Robert L.; Dougherty, Anne H.; Giebel, Ruth A.

In: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Vol. 5, No. 6, 01.01.1985, p. 298-311.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Amiodarone

T2 - Pharmacology and Antiarrhythmic and Adverse Effects

AU - Naccarelli, Gerald

AU - Rinkenberger, Robert L.

AU - Dougherty, Anne H.

AU - Giebel, Ruth A.

PY - 1985/1/1

Y1 - 1985/1/1

N2 - Amiodarone is a benzofuran derivative that has been effective for the treatment of both supraventricular and ventricular tachyarrhythmias. It has a large volume of distribution, moderate bioavailability and a long half‐life. Its pharmacokinetics are not well understood and its tissue distribution is not typical of a 2‐compartment model. Due to ocular, dermatologic, gastrointestinal, neurologic, cardiovascular, thyroid and pulmonary toxicity, amiodarone should be reserved for use in patients with refractory and/or life‐threatening arrhythmias. 1985 Pharmacotherapy Publications Inc.

AB - Amiodarone is a benzofuran derivative that has been effective for the treatment of both supraventricular and ventricular tachyarrhythmias. It has a large volume of distribution, moderate bioavailability and a long half‐life. Its pharmacokinetics are not well understood and its tissue distribution is not typical of a 2‐compartment model. Due to ocular, dermatologic, gastrointestinal, neurologic, cardiovascular, thyroid and pulmonary toxicity, amiodarone should be reserved for use in patients with refractory and/or life‐threatening arrhythmias. 1985 Pharmacotherapy Publications Inc.

UR - http://www.scopus.com/inward/record.url?scp=0022347632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022347632&partnerID=8YFLogxK

U2 - 10.1002/j.1875-9114.1985.tb03434.x

DO - 10.1002/j.1875-9114.1985.tb03434.x

M3 - Article

C2 - 2934688

AN - SCOPUS:0022347632

VL - 5

SP - 298

EP - 311

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 6

ER -